425: ReShape Lifesciences Adjourns Special Stockholder Meeting for Key Merger Votes

ReShape Lifesciences partially adjourned its Special Meeting of Stockholders to allow more time to solicit votes for the asset sale and charter amendment proposals, which are critical for its proposed merger with Vyome Therapeutics.

Summary

• ReShape Lifesciences conducted a Special Meeting of Stockholders on July 24, 2025, and partially adjourned it for Proposal 2 (Asset Sale Proposal) and Proposal 3 (Charter Amendment Proposal).
• All other proposals required for the merger with Vyome Therapeutics, Inc. were approved by stockholders.
• Approval of the Asset Sale Proposal (sale of substantially all assets to Ninjour Health International Limited, an affiliate of Biorad Medisys, Pvt. Ltd.) and the Charter Amendment Proposal are conditions to the consummation of the Merger.
• The Special Meeting of Stockholders will resume virtually on Thursday, August 7, 2025, at 11:30 a.m. Eastern Time, to vote on the adjourned proposals.
• The record date for determining eligible stockholders to vote remains June 9, 2025.
• Stockholders are encouraged to vote FOR Proposals 2 and 3 by calling 1-877-750-8310 (U.S. and Canada) or +1-412-232-3651 (other countries).

Sentiment

Score: 4

Explanation: While some merger proposals passed, the failure to approve two critical proposals (asset sale and charter amendment) and the need for an adjournment introduce uncertainty and delay into the merger process, which is a significant negative. The company's future is contingent on these approvals.

Positives

• All other proposals required for the merger with Vyome Therapeutics, Inc. were approved by stockholders.
• Management believes the proposed merger will maximize value for stockholders.

Negatives

• Two critical proposals (Asset Sale Proposal and Charter Amendment Proposal) did not receive sufficient votes for approval, necessitating an adjournment.
• The consummation of the merger is contingent upon the approval of the Asset Sale Proposal and the Charter Amendment Proposal, introducing uncertainty.

Risks

• Actual results could differ materially from forward-looking statements due to known and unknown risks, uncertainties, and other factors.
• Risks and uncertainties are described more fully in the company's filings with the Securities and Exchange Commission (SEC), including those factors identified as "risk factors" in the most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.

Future Outlook

The company intends to complete the merger with Vyome Therapeutics, which management believes will maximize value for stockholders. Vyome Therapeutics has announced its intent to be listed on the Nasdaq exchange under the ticker HIND pursuant to a reverse merger with ReShape Lifesciences Inc. in early 2025.

Management Comments

• "Our ability to complete the Merger, which we believe will maximize value for our stockholders, is contingent upon approval of the Asset Sale Proposal and the Charter Amendment Proposal." Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences.
• "Your vote for the Asset Sale Proposal is key to the Merger, and your vote for the Charter Amendment Proposal is important for the operation of the combined company following the Merger." Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences.

Industry Context

The proposed merger aims to establish a healthcare platform spanning the US-India innovation corridor, leveraging clinical-stage assets for immune-inflammatory conditions. This strategic move aligns with broader industry trends towards global expansion, particularly into emerging markets like India, to achieve cost efficiencies and expand market access in the med-tech and pharmaceutical sectors.

Corporate Governance

Related Party Transactions

• The Asset Sale Proposal involves the sale of substantially all of ReShape's assets to Ninjour Health International Limited, an affiliate of Biorad Medisys, Pvt. Ltd., as a condition to the proposed merger with Vyome Therapeutics, Inc.

Stakeholder Impact

• Shareholders are directly impacted by the merger's success, which management believes will maximize value. Their votes are crucial for the merger's completion, and the current adjournment introduces uncertainty.
• Customers may be impacted by the combined company's expanded offerings in weight loss, metabolic health, and immune-inflammatory conditions.

Next Steps

• Reconvened Special Meeting of Stockholders on August 7, 2025, at 11:30 a.m. Eastern Time, to vote on the Asset Sale Proposal and Charter Amendment Proposal.
• Continued solicitation of proxies from stockholders to vote FOR the Asset Sale Proposal and Charter Amendment Proposal.
• Consummation of the merger with Vyome Therapeutics, Inc. upon approval of the remaining proposals.

Key Dates

Recommendation

The merger is a significant event that could unlock value, but the delay and uncertainty surrounding the approval of critical proposals introduce risk. Investors should hold to see the outcome of the reconvened meeting before making further decisions, as the failure of these proposals would likely negatively impact the stock.

Keywords

Merger, Acquisition, Special Meeting, Stockholder Vote, Proxy Solicitation, Corporate Governance, Asset Sale, Charter Amendment, Healthcare, Medical Devices, Weight Loss, Metabolic Health, Vyome Therapeutics, Biorad Medisys, Nasdaq, RSLS